+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy



Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy



Circulation 110(6): 679-684



Paradoxically, fibrinolytic agents may systemically activate platelets, which in turn secrete plasminogen activator inhibitor (PAI-1), an antagonist of the fibrinolytic process in proportion to total body platelet mass. We hypothesized that improved epicardial patency, myocardial perfusion, and ST-segment resolution would be associated with higher levels of platelet receptor occupancy (RO) by a glycoprotein IIb/IIIa antagonist in ST-elevation MI (STEMI). Patients were drawn from the low-dose tenecteplase plus eptifibatide arm of the INTEGRITI study. Angiographic and platelet RO data were analyzed at 2 independent core laboratories. To take into account the absolute platelet count and receptors available for cross-linking, absolute platelet count was multiplied by percent of available receptors to obtain the index of the absolute number of receptors available (IANRA). Percent RO was higher among patients with a patent artery (TIMI flow grade 2/3; 78.2+/-9.2, n=63 versus 63.9+/-29.7, n=7; P=0.005), those with TIMI myocardial perfusion grade 2/3 (79.6+/-9.5, n=40 versus 73.0+/-16.2, n=30; P=0.036), and those with complete (> or =70%) ST-segment resolution at 60 minutes (81.3+/-8.3%, n=27 versus 73.1+/-17.4%, n=24; P=0.034). The absolute number of glycoprotein IIb/IIIa receptors available for cross-linking was reduced (ie, the IANRA was lower) among patients with a patent artery (P=0.0015), patients with TIMI myocardial perfusion grade 2/3 (P=0.026), and patients with > or =70% ST-segment resolution (P=0.029). This study links restoration of epicardial flow, normal myocardial perfusion, and complete ST-segment resolution with higher levels of platelet glycoprotein IIb/IIIa receptor occupancy after therapy with eptifibatide administered with tenecteplase.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011785581

Download citation: RISBibTeXText

PMID: 15262838

DOI: 10.1161/01.cir.0000137912.11655.f6


Related references

Association between platelet receptor occupancy after eptifibatide therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction - An INTEGRITI Integrilin and tenecteplase in acute myocardial infarction substudy. Circulation 110(6): 679-684, 2004

Increased platelet receptor occupancy following eptifibatide therapy is associated with improved patency, tissue level perfusion, and ST-segment resolution in ST-segment elevation myocardial infarction An INTEGRITI Substudy. Journal of the American College of Cardiology 41(6 Suppl. A): 391A, 2003

Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: Results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) phase II angiographic trial. Journal of the American College of Cardiology 41(8): 1251-1260, 2003

Combination reperfusion therapy with eptifibatide and tenecteplase for acute myocardial infarction. Design and methodology of the INTEGRITI (Integrilin and Tenecteplase for Acute Myocardial Infarction) trial. HeartDrug 1(1): 5-13, 2001

Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. American Heart Journal 152(4): 668-675, 2006

Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. European Heart Journal 26(19): 1971-1977, 2005

Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circulation. Cardiovascular Interventions 2(4): 330-338, 2009

Restoration of epicardial and myocardial perfusion in acute ST-elevation myocardial infarction with combination eptifibatide + reduced-dose tenecteplase Dose-finding results from the INTEGRITI trial. Circulation 104(17 Suppl.): II 538, 2001

Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. Journal of the American College of Cardiology 43(4): 549-556, 2004

Association of TIMI myocardial perfusion grade and ST-segment resolution with cardiovascular magnetic resonance measures of microvascular obstruction and infarct size following ST-segment elevation myocardial infarction. Journal of Thrombosis and Thrombolysis 27(2): 123-129, 2009

Prevalence and prognostic implications of ST-segment deviations from ambulatory Holter monitoring after ST-segment elevation myocardial infarction treated with either fibrinolysis or primary percutaneous coronary intervention (a Danish Trial in Acute Myocardial Infarction-2 Substudy). American Journal of Cardiology 100(6): 937-943, 2007

Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial). American Journal of Cardiology 121(9): 1039-1045, 2018

AS-96: The 12-Month Clinical Outcomes of Acute ST-Segment Elevation Myocardial Infarction Versus Acute NonST-Segment Elevation Myocardial Infarction in Patients with Previous Acute Myocardial Infarction. American Journal of Cardiology 105(9-Supp-S): 41-0, 2010

Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. Journal of the American College of Cardiology 45(2): 321-323, 2005

Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: The GUSTO-I ST segment monitoring substudy. Journal of the American College of Cardiology 31(4): 783-789, 1998